Monday, January 7, 2013 – 11:54:00
Effective January 1, Takeda Italia Farmaceutici SpA and Nycomed SpA become a single operating entity under the name of Takeda Italia SpA. Italy remains an important market, and the new company has a solid organization and a strong product pipeline, fully capable of promoting sustainable growth.
Today the new Takeda is more competitive than ever and is part of a global business entity, Takeda Pharmaceutical Company Limited, which is the largest pharmaceutical company in Asia and the 12th largest in the world. Looking at Italian data, Takeda is a major player in the domestic market, with projected net sales of over €300 million for fiscal year 2012 (ending March 2013). The new entity has its commercial headquarters in Rome with a total workforce of 521 employees, including internal personnel, medical-scientific information and production. Its plant in Cerano, near Milan, is one of the most advanced research and production centers in Europe.
From a commercial point of view, the new Takeda will move towards more targeted primary care, towards oncology and specialist areas, counting on three Business Units: Oncology, Specialties/Hospital and Retail. The Areas Specialties/Hospital Business Unit will have the task of successfully launching the new products in the pipeline, demonstrating the Company's solid commitment to supplying innovative medicines to Italian patients.
Today, Takeda ranks 7th in the world in the ranking of pharmaceutical companies by number of products under investigation, advancing five positions from 2011. In particular, the Takeda portfolio will be completely revitalized, with a development of the oncology area (where there are very important clinical results with brentuximab vedotin) and the onco-urology area (with TAK-700 for prostate cancer). The Group will also launch new molecules in the sectors in which it is already firmly present: cardiology (treatment of hypertension with Azilsartan) and diabetes (treatment of type 2 diabetes mellitus with Alogliptin).
The gastroenterology area will also be further developed, through the launch of a new drug for the treatment of UCU (ulcerative colitis rectum, with vedolizumab). The nephrology area will be covered with a drug for the treatment of anemia associated with chronic renal failure in patients on dialysis (peginesatide), while the neurology area could benefit from a new treatment for schizophrenia (lurasidone). A passion for discovery underpins Takeda's ability to provide therapeutic solutions in Italy and elsewhere
